Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust ...

A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models ...

A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, ...

On the Business of Biotech this week, industry veteran Dr. Jeremy Levin, Founder, Chairman, and former CEO at Ovid Therapeutics, sits down alongside the 2026 BIO Convention to talk about why public ...

Industry Explorers Blaze On: A series of stories of longtime leaders, still active in the industry, sharing their historical perspectives on life sciences industry innovation. A consuming interest, ...

In this week's episode of the Business of Biotech -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an ...

What happened at BIO? This selected coverage from the BIO 2026 meeting in San Francisco includes highlights from panels on ...

Speed alone no longer guarantees success; here’s what matters most in today’s launch environment. In today’s launch environment, order of entry (OOE) isn’t destiny. Many brands still anchor strategy ...

Life Science industry experts from Life Science Leaders editorial advisory board answer your questions ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

Drug and device manufacturers have long sought clearer rules for sharing scientific information about unapproved (off-label) uses of their products with health care providers (“HCPs”). In January 2025 ...

In the increasingly complex world of artificial intelligence (AI), the concept of "correct outcomes" takes on a profound and sometimes ambiguous meaning. Although efforts are made to create AI that ...